114 related articles for article (PubMed ID: 9973420)
1. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.
Kovarik J; Bozzotti P; Love-Homan L; Pihlgren M; Davis HL; Lambert PH; Krieg AM; Siegrist CA
J Immunol; 1999 Feb; 162(3):1611-7. PubMed ID: 9973420
[TBL] [Abstract][Full Text] [Related]
2. Cytosine-phosphate-guanine motifs fail to promote T-helper type 1-polarized responses in human neonatal mononuclear cells.
Prescott SL; Irwin S; Taylor A; Roper J; Dunstan J; Upham JW; Burgner D; Richmond P
Clin Exp Allergy; 2005 Mar; 35(3):358-66. PubMed ID: 15784116
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.
Zimmermann S; Egeter O; Hausmann S; Lipford GB; Röcken M; Wagner H; Heeg K
J Immunol; 1998 Apr; 160(8):3627-30. PubMed ID: 9558060
[TBL] [Abstract][Full Text] [Related]
4. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
5. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting.
Barrios C; Brawand P; Berney M; Brandt C; Lambert PH; Siegrist CA
Eur J Immunol; 1996 Jul; 26(7):1489-96. PubMed ID: 8766551
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model.
Kootiratrakarn T; Fujimura T; Sano K; Okuyama R; Aiba S; Tagami H; Terui T
Eur J Immunol; 2005 Nov; 35(11):3277-86. PubMed ID: 16245360
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
8. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
9. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
10. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
[TBL] [Abstract][Full Text] [Related]
11. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
Tengvall S; Josefsson A; Holmgren J; Harandi AM
J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
Vasilakos JP; Smith RM; Gibson SJ; Lindh JM; Pederson LK; Reiter MJ; Smith MH; Tomai MA
Cell Immunol; 2000 Aug; 204(1):64-74. PubMed ID: 11006019
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
[TBL] [Abstract][Full Text] [Related]
15. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice.
Zhu FG; Kandimalla ER; Yu D; Tang JX; Agrawal S
Int Immunopharmacol; 2004 Jul; 4(7):851-62. PubMed ID: 15182725
[TBL] [Abstract][Full Text] [Related]
16. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
Encke J; zu Putlitz J; Stremmel W; Wands JR
Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
[TBL] [Abstract][Full Text] [Related]
17. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs.
Sun CM; Deriaud E; Leclerc C; Lo-Man R
Immunity; 2005 Apr; 22(4):467-77. PubMed ID: 15845451
[TBL] [Abstract][Full Text] [Related]
18. The mouse chorionic gonadotropin beta-subunit-like (muCG beta l) molecule produced by tumor cells elicits the switch of T-cell immunity response from TH2 to TH1 in mice immunized with DNA vaccine based on rhesus monkey homologous CG beta (rmCG beta).
Shi SQ; Peng JP; Xu L; Yang Y; Chen Y
J Gene Med; 2005 Jan; 7(1):87-96. PubMed ID: 15517553
[TBL] [Abstract][Full Text] [Related]
19. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12.
Schirmbeck R; Reimann J
Intervirology; 2001; 44(2-3):115-23. PubMed ID: 11509872
[TBL] [Abstract][Full Text] [Related]
20. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
